Luffer-Atlas D[au] - Search Results

Year	Number of Results
1996	1
1997	2
1998	1
1999	1
2000	1
2003	1
2008	1
2009	2
2010	2
2012	2
2013	2
2016	1
2017	4
2018	5
2022	0

1

The early estimation of circulating drug metabolites in humans.

Luffer-Atlas D. Luffer-Atlas D. Expert Opin Drug Metab Toxicol. 2012 Aug;8(8):985-97. doi: 10.1517/17425255.2012.693159. Epub 2012 Jun 10. Expert Opin Drug Metab Toxicol. 2012. PMID: 22681256 Review.

2

Overview of metabolite safety testing from an industry perspective.

Anderson S, Knadler MP, Luffer-Atlas D. Anderson S, et al. Among authors: luffer atlas d. Bioanalysis. 2010 Jul;2(7):1249-61. doi: 10.4155/bio.10.67. Bioanalysis. 2010. PMID: 21083238 Review.

3

Unique/major human metabolites: why, how, and when to test for safety in animals.

Luffer-Atlas D. Luffer-Atlas D. Drug Metab Rev. 2008;40(3):447-63. doi: 10.1080/03602530802186561. Drug Metab Rev. 2008. PMID: 18642142 Review.

4

A decade of drug metabolite safety testing: industry and regulatory shared learning.

Luffer-Atlas D, Atrakchi A. Luffer-Atlas D, et al. Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):897-900. doi: 10.1080/17425255.2017.1364362. Epub 2017 Aug 11. Expert Opin Drug Metab Toxicol. 2017. PMID: 28797172 No abstract available.

5

Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1.

Leohr JK, Luffer-Atlas D, Luo MJ, DeBrota DJ, Green C, Mabry TE, Suico JG. Leohr JK, et al. Among authors: luffer atlas d. J Clin Pharmacol. 2018 Apr;58(4):412-424. doi: 10.1002/jcph.1032. Epub 2017 Nov 26. J Clin Pharmacol. 2018. PMID: 29178617 Clinical Trial.

6

Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury.

Norman BH, Fisher MJ, Schiffler MA, Kuklish SL, Hughes NE, Czeskis BA, Cassidy KC, Abraham TL, Alberts JJ, Luffer-Atlas D. Norman BH, et al. Among authors: luffer atlas d. J Med Chem. 2018 Mar 8;61(5):2041-2051. doi: 10.1021/acs.jmedchem.7b01806. Epub 2018 Feb 15. J Med Chem. 2018. PMID: 29425457

7

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.

Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL Jr, Conti I, Heathman M, Cronier DM. Mo G, et al. Among authors: luffer atlas d. Clin Pharmacokinet. 2018 Mar;57(3):355-365. doi: 10.1007/s40262-017-0562-0. Clin Pharmacokinet. 2018. PMID: 28620891 Free PMC article. Clinical Trial.

8

PDGFRα monoclonal antibody: Assessment of embryo-fetal toxicity and time-dependent placental transfer of a murine surrogate antibody of olaratumab in mice.

Luffer-Atlas D, Reddy VR, Hilbish KG, Grace CE, Breslin WJ. Luffer-Atlas D, et al. Birth Defects Res. 2018 Nov 1;110(18):1358-1371. doi: 10.1002/bdr2.1403. Epub 2018 Oct 27. Birth Defects Res. 2018. PMID: 30367709

9

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.

Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ 3rd, Guo Q, Iyer S, Rubin BP, Stancato L. Lowery CD, et al. Among authors: luffer atlas d. Clin Cancer Res. 2018 Feb 15;24(4):847-857. doi: 10.1158/1078-0432.CCR-17-1258. Epub 2017 Nov 30. Clin Cancer Res. 2018. PMID: 29191969

10

Predicting circulating human metabolites: how good are we?

Anderson S, Luffer-Atlas D, Knadler MP. Anderson S, et al. Among authors: luffer atlas d. Chem Res Toxicol. 2009 Feb;22(2):243-56. doi: 10.1021/tx8004086. Chem Res Toxicol. 2009. PMID: 19138063

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results